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A CASE OF CA19-9 PRODUCING TRANSITIONAL 
CELL CARCINOMA OF THE URETER 
Hironobu YAMAMOTO， Yasuo UEDA， Takuo MARUYAMA， Nobuyuki KONDOU， 
Michio NOJIMA， Hidekazu T AKIUCHI， Yoshinori MORI and Hiroki SHIMA 
From the Department 0] Urology，めogoCollege 0] Medicine 
Akira KUBOTA 
From the Department 0] Clinical Pathology，めogoCollege 0] Medicine 
れTereport a case of CA19-9 producing urothelial carcinoma of the right ureter. A 61-year-old 
male patient who had an extremely high value of serum CA19・9 (1，185 U/ml) with right 
hydronephrosis was referred to us. Magnetic resonance urography and retrograde ureterography 
revealed a long irregular filling defect in the right distal ureter. Under the diagnosis of right ureteral 
tumor， we performed right total nephroureterectomy and pelvic lymphadenectomy. The tumor was 
histologically diagnosed as grade 1 transitional cell carcinoma and pelvic lymphnodes were positive 
(pTIN2MO). The tumor cells showed positive immunostaining for CA19・9. The serum CA19-9 
level was normalized after the operation and successive adjuvant chemotherapy (M・VAC 2 course). 
No recurrence was found for 15 months after operation. In this case， the serum CA19θlevel was 
useful as a tumor marker. 
(Acta Urol. Jpn. 49: 543-545， 2003) 
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Fig. 1. MR-urography showed right hydro-
nephroureter and the filling defect of 


























示す部分を認めた 病理診断は移行上皮癌， grade 1， 
INFα， pT1， pRO， pLO， pVOであったが，右閉鎖
および外腸骨リンパ節に転移を認めた. TNM分類は
pT1N2MO (stage IV b)であったため， adjuvant 
therapyとして M-VAC療法を 2コース施行した.
Fig. 2. 乱1icroscopic findings of the right 
ureteraI tumor showed transitionaI ceIl 
carcinoma， Grade 1. 
Fig. 3. Immunohistochemical study showed 
diffuse positive finding in the cyto-





























































1) Koprowski H， Steplewski Z， Mitchell K， et al.: 
Colorectal carcinoma antigen detected by hybryd-
oma antibodies. Somat Cell Mol Genet 5: 957-
972， 1979 
2) Atkinson AM， Samia AS， Medhat K， et al.: 
Gastrointestinal cancer associated antigen in 








五七 35: 1425-1429， 1997 
5) Oshio G， Ogawa K， Kudo H， etal. : Immunohisto-
chemical distribution ofCA19-9 in normal tissues of 
the kidney. U rol Int 45: 1， 1990 
6)香川 征，田中敏博，住吉義光，ほか・ 1必尿器科
腫蕩における CA19-9測定の意義.西日泌尿
49: 1395-1398， 1987 
7)伊藤周二，西川慶一郎，後藤武，ほか:血清
CA19-9値と CA-125値が高値を示した腎結石に




尿器外科 8: 651-653， 1995 
9)近藤慶一，野口純男，執印太郎，ほか.血中
Span-I抗原およびCA19-9の異常高値を呈した尿








84: 1074-1081， 1993 
12)能登顕彰，藤B 真，磯部英行，ほか:尿路上皮
癌における尿 CA19-9値の測定 その診断的役割
の検討一 日泌、尿会誌 88: 406-413， 1997 
13) Abel PD， Cornell C， Buamah PK， et al.: 
Assessment ofserum CA19-9 as a tumor marker in 
patients with carcinoma ofthe bladder and prostate. 
Br J Urol 59: 427-429， 1987 
14)児玉一恵，定方宏人，見供修，ほか:CA19-9 





16) Taki T， Ho吋 aN， Yamada Y， et al.: CA19-9 
producing transitiomal cel carcinoma of the renal 
pelvis. a case report. 泌尿紀要 47:191-193， 
2001 
17)瀬川直樹，山本員久，和辻利和，ほか:CA19-9 
産生腎尿管腫蕩の l例.泌尿紀要 43: 665-668， 
1997 
(ReceM onApril7，州
Accepted on June 13， 20031 
